Compare RYAM & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAM | YDES |
|---|---|---|
| Founded | 1926 | 2013 |
| Country | United States | Taiwan |
| Employees | 2325 | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.8M | 543.0M |
| IPO Year | 2014 | N/A |
| Metric | RYAM | YDES |
|---|---|---|
| Price | $8.97 | $2.80 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 700.8K | 12.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $2.88 |
| 52 Week High | $11.85 | $25.00 |
| Indicator | RYAM | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 29.71 |
| Support Level | $8.22 | N/A |
| Resistance Level | $9.34 | $5.36 |
| Average True Range (ATR) | 0.37 | 0.40 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 74.67 | 17.57 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.